The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | ARCHIVE conditioning for upfront alloSCT in active AML and high-risk MDS-IB2
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the results of a study using an investigative conditioning regimen with alkylating agents, cytarabine, cladribine, hypomethylating agents, and venetoclax (ARCHIVE) for upfront allogeneic stem cell transplantation (alloSCT) in patients with poor-risk newly diagnosed or relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with increased blasts-2 (MDS-IB2). The study demonstrated a complete remission rate (CRR) of 96% and a measurable residual disease (MRD) negativity rate of 91%, with acceptable toxicity. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
